GRB7 is an oncogenic driver and potential therapeutic target in oesophageal adenocarcinoma

被引:9
|
作者
Gotovac, Jovana R. [1 ,2 ]
Liu, David S. H. [1 ,2 ]
Yates, Michael J. [1 ]
Milne, Julia, V [1 ,2 ]
Macpherson, Arthi A. [1 ]
Simpson, Kaylene J. [1 ,2 ]
Eslick, Guy D. [3 ]
Mitchell, Catherine [1 ,4 ]
Duong, Cuong P. [1 ,2 ]
Phillips, Wayne A. [1 ,2 ,5 ]
Clemons, Nicholas J. [1 ,2 ]
机构
[1] Peter MacCallum Canc Ctr, Div Canc Res, 305 Grattan St, Melbourne, Vic 3000, Australia
[2] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic, Australia
[3] Univ Sydney, Nepean Clin Sch, Kingswood, NSW, Australia
[4] Peter MacCallum Canc Ctr, Dept Pathol, Melbourne, Vic, Australia
[5] Univ Melbourne, St Vincents Hosp, Dept Surg, Parkville, Vic, Australia
来源
JOURNAL OF PATHOLOGY | 2020年 / 252卷 / 03期
基金
英国医学研究理事会; 澳大利亚国家健康与医学研究理事会;
关键词
oesophageal adenocarcinoma (OAC); GRB7; oncogene; HER2; ERBB2; trastuzumab; targeted therapy; receptor tyrosine kinase; reverse phase protein array (RPPA); BREAST-CANCER; CELL-GROWTH; TRASTUZUMAB; INHIBITION; ERBB2; HER2; LEISHMANIASIS; AMPLIFICATION; CHEMOTHERAPY; APOPTOSIS;
D O I
10.1002/path.5528
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Efficacious therapeutic approaches are urgently needed to improve outcomes in patients with oesophageal adenocarcinoma (OAC). However, oncogenic drivers amenable to targeted therapy are limited and their functional characterisation is essential. Among few targeted therapies available, anti-human epidermal growth factor receptor 2 (HER2) therapy showed only modest benefit for patients with OAC. Herein, we investigated the potential oncogenic role of growth factor receptor bound protein 7 (GRB7), which is reported to be co-amplified with HER2 (ERBB2) in OAC. GRB7 was highly expressed in 15% of OAC tumours, not all of which could be explained by co-amplification with HER2, and was associated with a trend for poorer overall survival. Knockdown of GRB7 decreased proliferation and clonogenic survival, and induced apoptosis. Reverse phase protein array (RPPA) analyses revealed a role for PI3K, mammalian target of rapamycin (mTOR), MAPK, and receptor tyrosine kinase signalling in the oncogenic action of GRB7. Furthermore, the GRB7 and HER2 high-expressing OAC cell line Eso26 showed reduced cell proliferation upon GRB7 knockdown but was insensitive to HER2 inhibition by trastuzumab. Consistent with this, GRB7 knockdownin vivowith an inducible shRNA significantly inhibited tumour growth in cell line xenografts. HER2 expression did not predict sensitivity to trastuzumab, with Eso26 xenografts remaining refractory to trastuzumab treatment. Taken together, our study provides strong evidence for an oncogenic role for GRB7 in OAC and suggests that targeting GRB7 may be a potential therapeutic strategy for this cancer. (c) 2020 The Authors.The Journal of Pathologypublished by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
引用
收藏
页码:317 / 329
页数:13
相关论文
共 50 条
  • [41] Matrix Metalloproteinase 11 Is a Potential Therapeutic Target in Lung Adenocarcinoma
    Yang, Haoran
    Jiang, Peng
    Liu, Dongyan
    Wang, Hong-Qiang
    Deng, Qingmei
    Niu, Xiaojie
    Lu, Li
    Dai, Haiming
    Wang, Hongzhi
    Yang, Wulin
    MOLECULAR THERAPY-ONCOLYTICS, 2019, 14 : 82 - 93
  • [42] CAMKII HYPERACTIVATION IN SKELETAL MUSCLES IS A DRIVER AND POTENTIAL THERAPEUTIC TARGET OF SARCOPENIA
    Wang, Qinchuan
    Bene, Michael
    Fountain, William
    Rosales-Soto, Giovanni
    Hernandez-Ochoa, Erick
    Chung, Tae Hwan
    Walston, Jeremy
    INNOVATION IN AGING, 2024, 8 : 871 - 871
  • [43] Glioma Cell Secretion: A Driver of Tumor Progression and a Potential Therapeutic Target
    Bonnin, Damian A. Almiron
    Havrda, Matthew C.
    Israel, Mark A.
    CANCER RESEARCH, 2018, 78 (21) : 6031 - 6039
  • [44] The role of MIF in periodontitis: A potential pathogenic driver, biomarker, and therapeutic target
    Fang, Tongfeng
    Liu, Liu
    Song, Dongzhe
    Huang, Dingming
    ORAL DISEASES, 2024, 30 (03) : 921 - 937
  • [45] ABERRANTLY GLYCOSYLATED MUC1 AS A POTENTIAL THERAPEUTIC TARGET FOR BARRETT'S WITH HIGH GRADE DYSPLASIA AND PRIMARY AND METASTATIC OESOPHAGEAL ADENOCARCINOMA
    Butt, M. A.
    Pye, H.
    Haidry, R. J.
    Oukrif, D.
    Rashid, M.
    Banks, M. R.
    Deonarain, M. P.
    Novelli, M. R.
    Lovat, L. B.
    GUT, 2012, 61 : A301 - A301
  • [46] Aberrantly Glycosylated MUC1 as a Potential Therapeutic Target for Barrett's With High Grade Dysplasia and Primary and Metastatic Oesophageal Adenocarcinoma
    Butt, Mohammed A.
    Pye, Hayley
    Haidry, Rehan J.
    Oukrif, Dahmane
    Deonarain, Mahendra
    Novelli, Marco
    Lovat, Laurence
    GASTROENTEROLOGY, 2012, 142 (05) : S526 - S526
  • [47] The Role of CtBP1 in Oncogenic Processes and Its Potential as a Therapeutic Target
    Blevins, Melanie A.
    Huang, Mingxia
    Zhao, Rui
    MOLECULAR CANCER THERAPEUTICS, 2017, 16 (06) : 981 - 990
  • [48] Evaluation of Cyclic Peptide Inhibitors of the Grb7 Breast Cancer Target: Small Change in Cargo Results in Large Change in Cellular Activity
    Sang, Jianrong
    Kulkarni, Ketav
    Watson, Gabrielle M.
    Ma, Xiuquan
    Craik, David J.
    Henriques, Sonia T.
    Poth, Aaron G.
    Benfield, Aurelie H.
    Wilce, Jacqueline A.
    MOLECULES, 2019, 24 (20):
  • [49] The many facets of miR-223 in cancer: Oncosuppressor, oncogenic driver, therapeutic target, and biomarker of response
    Favero, Andrea
    Segatto, Ilenia
    Perin, Tiziana
    Belletti, Barbara
    WILEY INTERDISCIPLINARY REVIEWS-RNA, 2021, 12 (06)
  • [50] The potential of AR-V7 as a therapeutic target
    Uo, Takuma
    Plymate, Stephen R.
    Sprenger, Cynthia C.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2018, 22 (03) : 201 - 216